Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 7/20 | 0.43 |
| ▸ | MAOA | P21397 | 3/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.41 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155497 | 0.92 | VDR (0.46) | VDRMAOBMAOANR4A2F2 | |
| SCHEMBL2107509 | 0.90 | F2 (0.44) | VDRMAOBMAOANR4A2F2 | |
| SCHEMBL2781757 | 0.89 | VDR (0.48) | VDRMAOB | |
| SCHEMBL2781788 | 0.88 | VDR (0.70) | VDRMAOBMAOANR4A2F2 | |
| SCHEMBL2782692 | 0.84 | VDR (0.40) | VDRF2 | |
| SCHEMBL2801791 | 0.82 | VDR (0.80) | VDRMAOBMAOANR4A2F2 | |
| SCHEMBL2801798 | 0.82 | VDR (0.80) | VDRMAOBMAOANR4A2F2 | |
| SCHEMBL2801805 | 0.82 | VDR (0.80) | VDRMAOBMAOANR4A2F2 | |
| SCHEMBL7775774 | 0.81 | VDR (0.43) | VDRMAOBMAOANR4A2F2 | |
| SCHEMBL6157125 | 0.81 | VDR (0.55) | VDRMAOBMAOANR4A2NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1686972-B1 | SPRAYABLE COMPOSITION FOR THE ADMINISTRATION OF VITAMIN D DERIVATIVES | GALDERMA RES & DEV (FR) | 2008-03-12 | — | — | EP | claimed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | claimed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | claimed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | claimed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | claimed |
| EP-2251004-A2 | Pharmaceutical or cosmetic composition and a mixed solubilisation method for the production thereof | Galderma Research & Development (FR) | 2010-11-17 | — | — | EP | disclosed |
| EP-1951199-A2 | PHARMACEUTICAL OR COSMETIC COMPOSITION AND A MIXED SOLUBILISATION METHOD FOR THE PRODUCTION THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007057598-A2 | PHARMACEUTICAL OR COSMETIC COMPOSITION AND A MIXED SOLUBILISATION METHOD FOR THE PRODUCTION THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-24 | — | — | WO | disclosed |
| EP-1753436-A2 | ANHYDROUS PHARMACEUTICAL COMPOSITION ASSOCIATING A SILICONATED AGENT AND SOLUBILISED ACTIVE PRINCIPLE | Galderma Research & Development (FR) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005092347-A2 | ANHYDROUS PHARMACEUTICAL COMPOSITION ASSOCIATING A SILICONATED AGENT AND SOLUBILISED ACTIVE PRINCIPLE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2005-10-06 | — | — | WO | disclosed |
| EP-1124779-B1 | VITAMIN D ANALOGUES | GALDERMA RES & DEV (FR) | 2005-02-02 | — | — | EP | disclosed |
| US-6689922-B1 | BIAROMATIC COMPOUNDS WHICH ARE ANALOGUES OF VITAMIN D HAVE A MARKED ACTIVITY IN THE FIELDS OF CELL DIFFERENTIATION AND PROLIFERATION | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-10 | — | — | US | disclosed |
| EP-1124779-A1 | VITAMIN D ANALOGUES | Galderma Research & Development, S.N.C. (FR) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026167-A1 | VITAMIN D ANALOGUES | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2000-05-11 | — | — | WO | disclosed |